Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

5.050 -0.070 (-1.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 175,042
Open 5.120
Bid (Size) 5.060 (1)
Ask (Size) 5.220 (6)
Prev. Close 5.120
Today's Range 5.000 - 5.540
52wk Range 3.020 - 18.10
Shares Outstanding 20,225,921
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
From Syros Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+42.66%
+42.66%
1 Month
+41.85%
+41.85%
3 Month
+25.62%
+25.62%
6 Month
-48.21%
-48.21%
1 Year
-70.98%
-70.98%

More News

Read More
Syros Announces Clinical Updates and 2023 Strategic Priorities
From Syros Pharmaceuticals
Via Business Wire
Analyst Expectations for Syros Pharmaceuticals's Future
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
From Syros Pharmaceuticals
Via Business Wire
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For November 14, 2022
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Looking Into Syros Pharmaceuticals's Recent Short Interest
Via Benzinga
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week
Via InvestorPlace
Grenwich LilfeSciences, Blue Apron And 3 More Short Squeeze Candidates That May Soar
Via Benzinga
10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.